Phase 2 N=7 Mechanisms of Refractory Hypertension (Reserpine)
Refractory Hypertension
Primary: Change Ambulatory Systolic Blood Pressure — -29.3 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=146 Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter
Hypertension
Primary: Change in Systolic and Diastolic Blood Pressure at Six (6) Months as Measured by Office-based Blood Pressure Assessment — -24.5; -10.3 mm Hg
N/A N=53 Efficacy and Safety of Radiofrequency Renal Denervation in Drug Resistant Hypertension
Hypertension
Primary: Change in Office Systolic BP — -31.1 mmHg — p=<0.0001
Phase 1 N=19 RENABLATE-II Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension - 157
Hypertension, Renal
Primary: Incidence of Major Adverse Events That Occurred Within 30 Days Post-procedure. — 0.0 percentage of participants
N/A N=106 Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)
Uncontrolled Hypertension
Primary: Office Systolic Blood Pressure Reduction — -31.7; 0.9 mmHg
N/A N=17 Controlling and Lowering Blood Pressure With The MOBIUSHD™
Hypertension
Primary: Adverse Events — 1; 1; 1; 1 participants
N/A N=47 Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients
Hypertension
Primary: Adverse Events — 47.8 percentage of participants
N/A N=17 Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment
Obstructive Sleep Apnea · Resistant Hypertension · Hyperaldosteronism
Primary: Severity of Obstructive Sleep Apnea — -18.3; 7.0 events/hour
N/A N=337 SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System
Hypertension · Vascular Diseases · Cardiovascular Diseases
Primary: Acute and Chronic Safety by Evaluating Incidence of Major Adverse Events — 204; 130; 2; 1 Participants
N/A N=30 Controlling and Lowering Blood Pressure With The MOBIUS HD™ (CALM-FIM_EUR)
Hypertension
Primary: Number of Participants With Serious Adverse Events (SAEs) — 8 Participants
N/A N=5 HIRREM for Stage 1 Primary Hypertension
Hypertension · Blood Pressure · Cardiovascular Diseases
Primary: Change From Baseline in Blood Pressure, as Measured by an Automated Oscillometric Blood Pressure Device. — -3.00; -6.67; -6.00; -7.67 mmHg
N/A N=265 Rheos® Pivotal Trial
Hypertension
Primary: Percent of Patients With a 10mmHg or Greater Reduction in Office Cuff Systolic Blood Pressure — 54.1; 46.4 percentage of participants
N/A N=366 SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study
Hypertension · Vascular Diseases · Cardiovascular Diseases
Primary: Number of Participants With Major Adverse Events (MAE) Defined as a Composite of Events. — 0; 0 Participants
Phase 2 N=189 An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
Resistant Hypertension
Primary: Dose-response (DR) Relationship of XXB750 With Respect to Change From Baseline in Systolic Blood Pressure (SBP) 24 Hours — -5.77; -6.41; -6.63; -6.66 mmHg — p=0.5651
N/A N=17 Renal Denervation for Management of Drug-Resistant Hypertension
Hypertension
Primary: Change in Systolic Blood Pressure From Baseline to 6 Months on 24-h Ambulatory Measurement (Follow-up Minus Baseline Measurement) — 0.7; -21.7 mmHg — p=0.018
Phase 3 N=730 A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety
Resistant Hypertension
Primary: Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Automated Office Blood Pressure Measurement…
N/A N=70 Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation
Atrial Fibrillation · Hypertension
Primary: Proportion of Subjects in Each Arm That Experience Safety Composite Events — 1; 3 Participants — p=0.28
N/A N=51 Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
Hypertension
Primary: OBSERVATIONAL: Change (Mean Reduction) in Average 24-hour Ambulatory Systolic Blood Pressure (ASBP) Through 8 Weeks — -5.3; -8.5 mmHg
Phase 2 N=14 The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension
Hypertension
Primary: Muscle Sympathetic Nerve Activity at Rest — 41; 43.8 bursts/minute
Phase 3 N=1,097 Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension
Hypertension
Primary: Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP) — -5.71; -7.95; -9.35; -10.63 mmHg — p=<0.0001
N/A N=45 The Peregrine Post-Market Study for the Treatment of Hypertension
Hypertension
Primary: Number of Subjects With the Absence of Particular Events as Adjudicated by the CEC Through 1-month Post Procedure: — 43 participants
Phase 2 N=34 Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients
Hypertension
Primary: Categorical Classification of Subjects Into Responders vs. Non-responders — 10; 2; 4; 19 Participants
N/A N=68 Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension
Renal Artery Stenosis · Hypertension, Renovascular
Primary: Primary Patency — 66 Subject-lesions — p=<.0001
N/A N=50 Rapid Renal Sympathetic Denervation for Resistant Hypertension
Hypertension, Resistant to Conventional Therapy
Primary: Acute Procedural Safety — 4 percentage of participants
N/A N=92 Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Systemic Arterial Hypertension · Hypertension Resistant to Conventional Therapy · Myocardial Infarction
Primary: Strokes, Either Fatal or Nonfatal — 24; 7 participants — p=0.19
Phase 2 N=275 A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)
Resistant Hypertension
Primary: Change From Baseline in Mean Seated Systolic BP (SBP) — -12.4; -17.3; -19.2; -9.8 mmHg
Phase 3 N=136 Midodrine for the Treatment of Refractory Hypotension
Hypotension · Critical Illness
Primary: Time Until Discontinuation of IV Vasopressors — 23.5; 22.5 hours
N/A N=55 Distal Renal Denervation
Hypertension, Resistant to Conventional Therapy
Primary: Changes of 24h-mean Systolic BP Assessed by Ambulatory Blood Pressure Monitoring (ABPM) — 21.1; 10.3 mmHg — p=0.045
N/A N=50 Adjunctive Renal Denervation in the Treatment of Atrial Fibrillation
Uncontrolled Hypertension · Atrial Fibrillation
Primary: Anti-arrhythmic Drug (AAD)-Free Single-procedure Freedom From Atrial Fibrillation Recurrence — 6; 2 recurrences
N/A N=60 Strategies for Aggressive Central Afterload Reduction in Patients With Heart Failure
Heart Failure
Primary: Change in Peak Oxygen Uptake (VO2) During Maximal Effort Exercise Stress Test According to Ejection Fraction Subgroups — 1.5; -0.5; 2.0; -1.0 percentage of change in…